webinar
Klebsiella pneumoniae Vaccine Development: Discovery to Clinic
Oct. 15, 2026 10:00 AM EDT I 3:00 PM BST
Register
Events
Meet BOC Sciences at AAPS PharmSci 360 2026 — Booth #811
Oct. 25–28, 2026, New Orleans, LA
Register
Shopping Cart 0
Tel:
Email:
Favipiravir (T-705) inhibits in vitro norovirus replication

Favipiravir (T-705) inhibits in vitro norovirus replication

Rocha-Pereira, J., Jochmans, D., Dallmeier, K., Leyssen, P., Nascimento, M. S. J., & Neyts, J.

Biochemical and biophysical research communications 424.4 (2012): 777-780.

Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment/prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.

Favipiravir-T-705-inhibits-in-vitro-norovirus-replication

Products Recommended in this Publication

B0084-463609

Favipiravir

For research use only
B2693-070289

Raltegravir

For research use only
B2692-291708

Remdesivir

For research use only
B2693-460490

Letermovir

For research use only
B2693-058383

Bictegravir

For research use only